Depression — Clinical Documentation Guide (2026)

🔍 Definition

Major Depressive Disorder (MDD) is a common, serious, and treatable mental health condition characterized by persistent depressed mood or loss of interest/pleasure (anhedonia) that causes significant impairment in social, occupational, or other domains of functioning. MDD is classified under the DSM-5-TR as a unipolar mood disorder, distinct from bipolar and related disorders (F31.x). According to USPSTF 2023 guidance, the 12-month prevalence of MDD in U.S. adults is approximately 10% and lifetime prevalence approaches 20%, making it one of the most frequently encountered diagnoses in both primary care and behavioral health settings.

For coding purposes, depression maps primarily to the ICD-10-CM categories F32 (single episode), F33 (recurrent), and related codes including F34.1 (persistent depressive disorder/dysthymia), F34.81 (disruptive mood dysregulation disorder), F53.x (perinatal depression), and F06.31–F06.32 (mood disorder due to known physiological condition). Precise documentation of episode type, severity, recurrence, and specifiers is critical for risk adjustment under the CMS-HCC Model V28, where only moderate and severe MDD generate payment HCC credit.

🗂️ Alternative Terminology

Clinical staff and patients use a wide range of terms that may correspond to a codeable depressive disorder. CDI specialists should flag these terms in documentation and query for diagnostic specificity.

🩺 Signs & Symptoms

DSM-5-TR requires at least five of the following nine symptoms during the same two-week period, with at least one being depressed mood or anhedonia, to meet criteria for a Major Depressive Episode. These criteria directly inform ICD-10-CM severity coding and PHQ-9 scoring (Kroenke et al., 2001):

• Depressed mood most of the day, nearly every day (subjective report or observation)
• Anhedonia — markedly diminished interest or pleasure in all, or almost all, activities
• Weight/appetite change — significant weight loss or gain (≥5% in one month), or decreased/increased appetite
• Sleep disturbance — insomnia or hypersomnia nearly every day
• Psychomotor agitation or retardation observable by others (not merely subjective feelings)
• Fatigue or loss of energy nearly every day
• Feelings of worthlessness or excessive/inappropriate guilt
• Cognitive impairment — diminished ability to think, concentrate, or make decisions
• Suicidal ideation — recurrent thoughts of death, suicidal ideation, or suicide attempt

PHQ-9 Severity Mapping (aligned with ICD-10-CM severity codes):

Additional clinical indicators beyond PHQ-9: suicidal ideation or behavior (code separately as R45.851 — suicidal ideations), psychotic features (delusions, hallucinations — upgrades severity to F32.3/F33.3), presence of peripartum onset, seasonal pattern, catatonic features, anxious distress specifier, and mixed features (review bipolar exclusion under F31.x Excludes1).

🧭 Differential Diagnosis

Accurate depression coding requires ruling out or separately coding the following conditions, several of which carry distinct ICD-10-CM codes and different HCC implications:

📋 Clinical Indicators for Coders/CDI

The following documentation elements in the medical record support assignment of a specific, HCC-eligible depression code. CDI should proactively query when these indicators are present without a corresponding documented diagnosis or without adequate specificity.

🦴 Anatomy & Pathophysiology

Depression is a neurobiological disorder involving multiple intersecting systems. Key pathophysiological mechanisms relevant to clinical documentation and CDI include:

Monoamine Hypothesis: The foundational model proposes that MDD results from deficient serotonergic (5-HT), noradrenergic (NE), and dopaminergic neurotransmission. This underpins the mechanism of action of SSRIs, SNRIs, and TCAs. While oversimplified, this model remains clinically relevant because antidepressant classes target different monoamine pathways, and documentation of medication history (and prior medication failures) supports TRD coding and Spravato medical necessity.

Glutamate / NMDA Receptor Pathway: Ketamine and esketamine (Spravato) act as NMDA receptor antagonists, producing rapid antidepressant effects within hours — contrasting with the 2–6 week onset of monoamine-targeting agents. This pathway is now central to TRD treatment and relevant to documenting treatment history for prior authorization and coding justification.

HPA Axis Dysregulation: Chronic stress activates the hypothalamic-pituitary-adrenal axis, elevating cortisol. Hypercortisolism is documented in MDD and is directly relevant when depression is secondary to a medical condition (e.g., Cushing disease, corticosteroid therapy — document as F06.31/F06.32 rather than primary F32.x).

Neuroinflammation and Neuroplasticity: Inflammatory cytokines (IL-6, TNF-α, CRP) are elevated in MDD and are associated with treatment resistance. Conditions such as autoimmune disease, metabolic syndrome, and chronic pain frequently co-occur with depression, requiring concurrent coding of all documented comorbidities.

Genetic and Epigenetic Factors: First-degree relatives of MDD patients have 2–3× elevated lifetime risk. Family history (Z81.8) is a relevant additional code and supports medical necessity documentation for enhanced screening (G0444) and preventive services.

💊 Medication Impact / Treatment

Documentation of pharmacotherapy is essential for CDI, coding specificity, and HCC capture. The following agents are commonly prescribed for MDD and have specific documentation implications:

First-Line Pharmacotherapy:

• SSRIs (fluoxetine, sertraline, escitalopram, citalopram, paroxetine, fluvoxamine): First-line for most MDD episodes. Presence on medication list is a strong clinical indicator of active depression diagnosis.
• SNRIs (venlafaxine, desvenlafaxine, duloxetine, levomilnacipran): Dual serotonin-norepinephrine reuptake inhibition; frequently used in depression with comorbid pain or anxiety.
• Atypicals:
  • Bupropion (Wellbutrin): Dopamine/norepinephrine reuptake inhibitor; preferred when sexual dysfunction or weight gain are concerns.
  • Mirtazapine (Remeron): Noradrenergic and specific serotonergic antidepressant (NaSSA); useful in elderly patients with insomnia/weight loss.
  • Vortioxetine (Trintellix): Multimodal serotonergic agent with cognitive benefit claims.

Second-Line and Augmentation:

• TCAs (amitriptyline, nortriptyline, imipramine): Older class; now mainly used for TRD augmentation or comorbid pain/insomnia. Narrow therapeutic index — toxicity monitoring relevant.
• MAOIs (phenelzine, tranylcypromine, selegiline patch): Reserved for atypical depression or TRD; dietary tyramine restrictions and drug interactions are critical documentation considerations.
• Lithium augmentation: Used in TRD; requires monitoring of serum levels, renal function, thyroid function — all coworthy comorbidities.
• Atypical antipsychotic augmentation (aripiprazole, quetiapine, brexpiprazole): FDA-approved adjuncts for MDD; relevant for documenting treatment complexity and severity.

Ketamine/Esketamine (TRD):

Esketamine (Spravato), an intranasal NMDA receptor antagonist, received FDA approval in March 2019 for TRD and for MDD with acute suicidal ideation. Treatment-resistant depression is defined operationally as failure of ≥2 adequate antidepressant trials in the current episode. There is no dedicated ICD-10-CM code for TRD — document and code the specific MDD code (F32.1, F32.2, F33.1, F33.2) that reflects current severity. HCPCS code J0013 is used to bill esketamine nasal spray (per mg). Documentation must include prior medication failures, current severity, and monitoring for dissociation/blood pressure elevation per REMS requirements.

Neuromodulation:

• Electroconvulsive Therapy (ECT): Most effective acute treatment for severe or psychotic MDD; relevant in inpatient DRG 876 (O.R. procedure with mental illness). Coded with CPT 90870 and ICD-10-PCS procedure codes.
• Transcranial Magnetic Stimulation (TMS): FDA-cleared for MDD; CPT 90867–90869; typically outpatient, covered by most commercial payers and Medicare for TRD.

Drug-Induced and Medical-Condition-Related Depression:

Several medications and medical conditions can precipitate depression requiring distinct coding:

• Corticosteroids (prednisone, methylprednisolone): Well-documented cause of mood disturbance — document as adverse effect (T38.0x5A) + F06.31 or F06.32 if physiological mechanism is documented by the treating provider.
• Interferon-alpha (used for HCV, certain malignancies): High rate of depression; code as adverse effect of T45.1x5A + F06.3x.
• Beta-blockers, isotretinoin, hormonal contraceptives: Associated with mood symptoms; provider documentation of causal relationship required before coding F06.3x.
• Medical conditions (hypothyroidism E03.x, Parkinson's disease G20.x, post-stroke F06.32, Huntington's disease G10, Alzheimer's G30.x): When the provider documents that the depression is a direct physiological consequence, assign F06.31 or F06.32 as the mood disorder code, plus the underlying medical condition.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO CDG members.